In post-treatment patient samples, 8 out of 11 melanoma samples had an increase in either ROS or FAM signatures, as well as 50% of HER2+ breast cancer samples, but the increase in HER2+ samples was only in the post-treatment samples[61]. Here, ERBB2 is linked to breast carcinoma.